Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells

References

• Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1–13. doi:10.1093/neuonc/nov189.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–820. doi:10.1007/s00401-016-1545-1.
   PubMed Web of Science ®Google Scholar
• Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15:405–417. doi:10.1038/s41582-019-0220-2.
   PubMed Web of Science ®Google Scholar
• Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:394. doi:10.1038/nrclinonc.2016.65.
   PubMed Web of Science ®Google Scholar
• Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017;8:91779–91794. doi:10.18632/oncotarget.21586.
   PubMedGoogle Scholar
• Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res. 2011;17:4296–4308. doi:10.1158/1078-0432.CCR-10-2557.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017;19:1460–1468. doi:10.1093/neuonc/nox054.
   PubMed Web of Science ®Google Scholar
• Richardson LG, Nieman LT, Stemmer-Rachamimov AO, Zheng XS, Stafford K, Nagashima H, Miller JJ, Kiyokawa J, Ting DT, Wakimoto H, et al. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 2020;9:1806662. doi:10.1080/2162402X.2020.1806662.
   PubMed Web of Science ®Google Scholar
• Amankulor NM, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M, Margineantu DH, Rao A, Bolouri H, Delrow J, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017;31:774–786. doi:10.1101/gad.294991.116.
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Maciejewski JP, Wilmink JW, Van Noorden C. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018;37:1949–1960. doi:10.1038/s41388-017-0077-z.
   PubMed Web of Science ®Google Scholar
• Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol. 2013;14:986–995. doi:10.1038/ni.2705.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12:623–635. doi:10.1038/nri3265.
   PubMed Web of Science ®Google Scholar
• Zeiner PS, Preusse C, Blank AE, Zachskorn C, Baumgarten P, Caspary L, Braczynski AK, Weissenberger J, Bratzke H, Reiß S, et al. MIF receptor CD74 is Restricted to microglia/ macrophages,associated with a M1-polarized immune milieu and prolonged patient survival in gliomas. Brain Pathol. 2015;25:491–504. doi:10.1111/bpa.12194.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Spranger S, Fuchs E, López-Soto A. WNT signaling in cancer immunosurveillance. Trends Cell Biol. 2019;29:44–65. doi:10.1016/j.tcb.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Ji L, Qian W, Gui L, Ji Z, Yin P, Lin GN, Wang Y, Ma B, Gao WQ. Blockade of beta-Catenin-induced CCL28 suppresses gastric cancer progression via inhibition of treg cell infiltration. Cancer Res. 2004–16;80:2020.
   Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–235. doi:10.1038/nature14404.
   PubMed Web of Science ®Google Scholar
• Cui D, Ren J, Shi J, Feng L, Wang K, Zeng T, Jin Y, Gao L. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/beta-catenin signaling. Int J Biochem Cell Biol. 2016;73:72–81. doi:10.1016/j.biocel.2016.02.007.
   PubMed Web of Science ®Google Scholar
• Yao Q, Cai G, Yu Q, Shen J, Gu Z, Chen J, Shi W, Shi J. IDH1 mutation diminishes aggressive phenotype in glioma stem cells. Int J Oncol. 2018;52:270–278. doi:10.3892/ijo.2017.4186.
   PubMed Web of Science ®Google Scholar
• Van Steenwinckel J, Schang A, Krishnan ML, Degos V, Delahaye-Duriez A, Bokobza C, Csaba Z, Verdonk F, Montané A, Sigaut S, et al. Decreased microglial Wnt/β-catenin signalling drives microglial pro-inflammatory activation in the developing brain. Brain. 2019;142:3806–3833. doi:10.1093/brain/awz319.
   PubMed Web of Science ®Google Scholar
• Moriguchi T, Kaneumi S, Takeda S, Enomoto K, Mishra SK, Miki T, Koshimizu U, Kitamura H, Kondo T. Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling. Oncoimmunology. 2016;5:e1242547. doi:10.1080/2162402X.2016.1242547.
   PubMed Web of Science ®Google Scholar
• Barberi T, Martin A, Suresh R, Barakat DJ, Harris-Bookman S, Drake CG, Lim M, Friedman AD. Absence of host NF-kappaB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother. 2018;67:1491–1503. doi:10.1007/s00262-018-2184-2.
   PubMed Web of Science ®Google Scholar
• Proffitt KD, Madan B, Ke Z, Pendharkar V, Ding L, Lee MA, Hannoush RN, Virshup DM. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 2013;73:502–507. doi:10.1158/0008-5472.CAN-12-2258.
   PubMed Web of Science ®Google Scholar
• Cai J, Chen Q, Cui Y, Dong J, Chen M, Wu P, Jiang C. Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples. Oncoimmunology. 2018;7(5):e1426516. doi:10.1080/2162402X.2018.1426516.
   PubMed Web of Science ®Google Scholar
• Zeiner PS, Preusse C, Golebiewska A, Zinke J, Iriondo A, Muller A, Kaoma T, Filipski K, Müller-Eschner M, Bernatz S, et al. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. Brain Pathol. 2019;29(4):513–529. doi:10.1111/bpa.12690.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15–24. doi:10.1002/path.2370.
   PubMed Web of Science ®Google Scholar
• Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17(2):170–182. doi:10.1038/ncb3090.
   PubMed Web of Science ®Google Scholar
• Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother. 2011;60:153–160. doi:10.1007/s00262-010-0946-6.
   PubMed Web of Science ®Google Scholar
• Qian J, Luo F, Yang J, Liu J, Liu R, Wang L, Wang C, Deng Y, Lu Z, Wang Y, et al. TLR2 promotes glioma immune evasion by downregulating MHC class II molecules in Microglia. Cancer Immunol Res. 2018;6:1220–1233. doi:10.1158/2326-6066.CIR-18-0020.
   PubMed Web of Science ®Google Scholar
• Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF, Dhara S, Simpson K, Gardner EE, Iacobuzio-Donahue CA, et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. 2016;17(9):2445–2459. doi:10.1016/j.celrep.2016.10.052.
   PubMed Web of Science ®Google Scholar
• Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, Brouland J-P, Iacobuzio-Donahue CA, Brennan C, Tabar V, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181(7):1643–1660.e17. doi:10.1016/j.cell.2020.05.007.
   PubMed Web of Science ®Google Scholar
• Bengoa-Vergniory N, Gorrono-Etxebarria I, Gonzalez-Salazar I, Kypta RM. A switch from canonical to noncanonical Wnt signaling mediates early differentiation of human neural stem cells. Stem Cells. 2014;32:3196–3208. doi:10.1002/stem.1807.
   PubMed Web of Science ®Google Scholar
• Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S, Lee SC. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35:306–328. doi:10.1111/j.1365-2990.2008.01006.x.
   PubMed Web of Science ®Google Scholar
• Beckers L, Ory D, Geric I, Declercq L, Koole M, Kassiou M, Bormans G, Baes M. Increased expression of translocator protein (TSPO) marks pro-inflammatory microglia but does not predict neurodegeneration. Mol Imaging Biol. 2018;20:94–102. doi:10.1007/s11307-017-1099-1.
   PubMed Web of Science ®Google Scholar
• Hu F, Ku MC, Markovic D, Dzaye O, Lehnardt S, Synowitz M, Wolf SA, Kettenmann H. Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. Int J Cancer. 2014;135:2569–2578. doi:10.1002/ijc.28908.
   PubMed Web of Science ®Google Scholar
• Matias D, Predes D, Niemeyer FP, Lopes MC, Abreu JG, Lima F, Moura Neto V. Microglia-glioblastoma interactions: new role for Wnt signaling. Biochim Biophys Acta Rev Cancer. 2017;1868:333–340. doi:10.1016/j.bbcan.2017.05.007.
   PubMed Web of Science ®Google Scholar
• Henrik HD, Ravi VM, Behringer SP, Frenking JH, Wurm J, Joseph K, Garrelfs NWC, Strähle J, Heynckes S, Grauvogel J, et al. Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. Nat Commun. 2019;10(1):2541. doi:10.1038/s41467-019-10493-6.
   PubMed Web of Science ®Google Scholar
• Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro Oncol. 2012;14:958–978.
   PubMed Web of Science ®Google Scholar
• Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5671–5682. doi:10.1158/0008-5472.CAN-16-0144.
   PubMed Web of Science ®Google Scholar
• Xue N, Zhou Q, Ji M, Jin J, Lai F, Chen J, Zhang M, Jia J, Yang H, Zhang J, et al. Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Sci Rep. 2017;7(1):39011. doi:10.1038/srep39011.
   PubMed Web of Science ®Google Scholar
• Chen D, Xie J, Fiskesund R, Dong W, Liang X, Lv J, Jin X, Liu J, Mo S, Zhang T, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 2018;9(1):873. doi:10.1038/s41467-018-03225-9.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Horlad H, Ohnishi K, Fujiwara Y, Bai B, Nakagawa T, Suzu S, Nakamura H, Kuratsu J-I, Takeya M, et al. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci. 2012;103:2165–2172. doi:10.1111/cas.12015.
   PubMed Web of Science ®Google Scholar
• Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, et al. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016;5(6):e1145332. doi:10.1080/2162402X.2016.1145332.
   PubMed Web of Science ®Google Scholar
• Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–1272. doi:10.1038/nm.3337.
   PubMed Web of Science ®Google Scholar
• Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy foundation early phase clinical trials consortium phase II study. Neuro Oncol. 2016;18(4):557–564. doi:10.1093/neuonc/nov245.
   PubMed Web of Science ®Google Scholar
• Kierdorf K, Prinz M. Microglia: same same, but different. J Exp Med. 2019;216:2223–2225. doi:10.1084/jem.20191535.
   PubMed Web of Science ®Google Scholar
• Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia. 2009;57:1458–1467.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Doring A, Zemp FJ, Silva C, Lun X, Wang X, Kelly J, Hader W, Hamilton M, Mercier P, et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci. 2014;17(1):46–55. doi:10.1038/nn.3597.
   PubMed Web of Science ®Google Scholar
• Kees T, Lohr J, Noack J, Mora R, Gdynia G, Todt G, Ernst A, Radlwimmer B, Falk CS, Herold-Mende C, et al. Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation. Neuro Oncol. 2012;14(1):64–78. doi:10.1093/neuonc/nor182.
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee JK, Ahn SH, Lee J, Nam DH. WNT signaling in glioblastoma and therapeutic opportunities. Lab Invest. 2016;96:137–150. doi:10.1038/labinvest.2015.140.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15:808–813.
   PubMed Web of Science ®Google Scholar
• Zhang D, Lu Z, Man J, Cui K, Fu X, Yu L, Gao Y, Liao L, Xiao Q, Guo R, et al. Wnt-3a alleviates neuroinflammation after ischemic stroke by modulating the responses of microglia/macrophages and astrocytes. Int Immunopharmacol. 2019;75:105760. doi:10.1016/j.intimp.2019.105760.
   PubMed Web of Science ®Google Scholar
• Yang Y, Ye YC, Chen Y, Zhao JL, Gao CC, Han H, Liu W-C, Qin H-Y. Crosstalk between hepatic tumor cells and macrophages via Wnt/beta-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors. Cell Death Dis. 2018;9:793. doi:10.1038/s41419-018-0818-0.
   PubMed Web of Science ®Google Scholar
• Matias D, Dubois LG, Pontes B, Rosário L, Ferrer VP, Balça-Silva J, Fonseca AC, Macharia LW, Romão L, Chimelli L, et al. GBM-derived Wnt3a induces M2-like phenotype in microglial cells through Wnt/β-catenin signaling. Mol Neurobiol. 2018;56:1517–1530. doi:10.1007/s12035-018-1150-5.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang J, Zheng H, Li C, Xiong J, Wang W, Bao H, Jin H, Liang P, Matias D. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. J Exp Clin Cancer Res. 2019;38(1):380. doi:10.1186/s13046-019-1371-0.
   PubMed Web of Science ®Google Scholar
• Pacella I, Cammarata I, Focaccetti C, Miacci S, Gulino A, Tripodo C, Ravà M, Barnaba V, Piconese S. Wnt3a neutralization enhances T-cell responses through indirect mechanisms and restrains tumor growth. Cancer Immunol Res. 2018;6:953–964. doi:10.1158/2326-6066.CIR-17-0713.
   PubMed Web of Science ®Google Scholar